Articles tagged with Liver Cancer
A study analyzing NY state cancer death data from 2008-2014 found high mortality rates among U.S.-born blacks and Puerto Ricans, while South American Hispanics had relatively low rates. The researchers also identified significant disparities in liver cancer mortality between these groups.
A study found a 65% increase in cirrhosis deaths and a doubling of liver cancer deaths among US adults between 1999 and 2016. Young people aged 25-34 experienced the highest average annual increase in cirrhosis deaths, driven by alcohol-related liver disease.
A study published in Communications Biology has linked the protein PARP1 to an aggressive form of pediatric liver cancer called hepatoblastoma. Researchers found that inhibiting PARP1 slowed or stopped cancer progression in laboratory tests, providing a potential treatment target for this disease.
Researchers at Mayo Clinic have developed a DNA test that can detect liver cancer with high accuracy, outperforming current methods. The test uses abnormal DNA markers found in liver cancer tissues and has been shown to detect over 90% of patients with curable stage tumors.
A new clinical trial is testing whether omega-3 capsules can stop bowel cancer from returning after liver surgery. The trial, funded by Yorkshire Cancer Research, involves 450 patients and investigates the effectiveness of a highly purified form of EPA.
A study confirms a curable state between single and widespread cancers by identifying molecular patterns that predict patient outcomes. Researchers found that patients with limited spread of disease could achieve prolonged survival with surgery or targeted radiation therapy.
The number of people receiving HCV cure is increasing with new, highly effective treatments available; simplification of treatment delivery can accelerate global scale-up. Cure leads to reductions in liver-related deaths and cancer risk, as well as improvements in comorbidities.
Researchers discovered mouse genes that enhance human T-cell power against liver cancer, offering new hope for patients. Engineered human T cells eradicated cancer without harming normal liver tissue.
Researchers identified a tumor suppressor protein called LHPP that can help diagnose and monitor liver cancer. Reintroducing LHPP into the liver of model mice prevented tumor formation, suggesting its potential as a new therapeutic approach for treating liver cancer.
Patients with alcohol-related liver cancer tend to have poorer overall survival rates compared to those with non-alcohol related liver cancer. The study highlights the need for improved screening and treatment programs for patients at risk of developing cirrhosis or liver cancer, especially those who are still drinking.
A recent study found that less than 13% of individuals born between 1945 and 1965 have undergone HCV screening. The researchers also noted a significant disparity in HCV screening rates among different ethnic groups, with Hispanics and non-Hispanic Blacks receiving lower rates of screening.
A large study of Japanese adults found a significant association between higher vitamin D levels and a lower risk of overall cancer, including liver cancer. The researchers observed a reduced relative risk of around 20% for overall cancer and 30-50% for liver cancer.
Researchers have developed a method to identify splicing-based biomarkers for hepatocellular carcinoma (HCC), the most common form of liver cancer. These biomarkers may help predict disease progression and are associated with poor patient survival.
Combining a blood test for high alpha fetoprotein (AFP) levels with ultrasound imaging improves liver cancer detection by 40 percent, according to researchers at UT Southwestern Medical Center. Early detection is crucial for improving survival rates in patients with liver cancer, which is on the rise in the US.
Researchers discovered that polyploid liver cells can protect the liver against cancer by carrying extra copies of tumor suppressor genes. This finding challenges the notion that polyploidy is a pro-cancer state and suggests it could be an adaptive response within normal liver cells.
Researchers have developed a new method to grow patient-derived xenografts (PDX) liver cancer cells in culture, which maintains their proper shape and function and grows as organoids. The success of the engineered organoids has the potential to revolutionize the screening and development of liver cancer drugs.
Researchers discover a two-step process to kill liver cancer cells by silencing an enzyme and adding metformin, potentially accelerating new treatments for this deadly disease. This approach has shown promise in treating liver cancer, where surgery is often not an option and available drugs are only moderately effective.
A study published in The Lancet Diabetes & Endocrinology found that diabetes and high BMI were responsible for 544,300 new cancer cases globally in 2012. The authors project a significant increase in the proportion of cancers attributable to these risk factors, particularly in low- and middle-income countries.
A study of over 200 studies found that moderate coffee drinking is associated with lower risks of death, heart disease, and certain cancers. However, high consumption during pregnancy or in women at risk of fracture may be detrimental. The authors suggest further randomized trials to confirm the findings.
Researchers discovered a synthetic double-stranded RNA that boosts anti-tumor innate immune functions, potentially preventing liver cancer. The study found that administering the RNA at different stages suppressed tumor formation in mouse models.
Researchers at the University of California San Diego School of Medicine found that chronic liver inflammation suppresses immunosurveillance, allowing cancer cells to grow. Inhibiting PD-L1 restored immune function and cleared tumors in mice with NASH-associated mutations.
Research shows long-term aspirin use significantly reduces digestive cancer incidence, with substantial reductions in liver and oesophageal cancers. Aspirin use also shows promise in reducing risk of certain other cancers, while raising cardiovascular risk when stopped.
A study by researchers from Duke-NUS Medical School and Taiwan found that liver cancers exposed to Aristolochic Acids have AA-related mutations, with high prevalence in East and Southeast Asia. The findings highlight the need for public education and awareness about the dangers of AA in herbal products.
A study published in Gastroenterology identifies the gene mutation responsible for fibrolamellar hepatocellular carcinoma, a rare form of liver cancer mainly affecting children and young people. The researchers used CRISPR/Cas9 technology to introduce the mutation into mice, resulting in 12 out of 15 developing tumors.
A USC research team has identified a potential therapeutic target for liver cancer treatment: mitophagy, the removal of damaged mitochondria. This process can cause tumors to proliferate, but temporarily halting it may reduce cancer stem cell growth, leading to tumor regression.
A new study estimates that there were 854,000 new cases of liver cancer and 810,000 deaths worldwide in 2015. The majority of these cases were attributed to hepatitis B virus and alcohol consumption, highlighting the need for prevention and treatment strategies.
Researchers found two types of T cells respond differently to cancer antigens, with one starting strong but exhausting quickly and the other staying on target for a longer antitumor effect. The study suggests that targeting the persistent T cell type could lead to more effective cancer vaccines.
Researchers discovered that caspase-8 triggers programmed cell death in diseased liver cells, leading to genetic instability and tumor development. This mechanism is remarkably universal across various liver diseases.
A recent study found that chronic cell death promotes the development of liver cancer by causing remaining cells to divide at higher rates. The researchers also identified caspase 8 as an enzyme playing a dual role in this process, involving both apoptosis and DNA repair.
Researchers at KAIST have developed a novel method to improve medication treatment for liver cancer, identifying the resistance mechanism of Sorafenib and discovering a new approach to block it. The study suggests the possibility of developing a new method to overcome drug resistance using network analysis.
Researchers have developed a rapid portable test for liver cancer that can detect the disease in two minutes and can be administered wherever the patient is. The test uses gold nanoparticles to trap biomarkers from biological fluids, making it a potential game-changer in combating this deadly disease.
A little-studied gene SLC13A5 may explain how liver cancer cells obtain energy to proliferate. Suppressing SLC13A5 in human hepatocellular carcinoma cell lines resulted in slower growth and division of cancer cells.
Researchers at the University of Missouri found that women with increased cadmium levels have a higher risk of endometrial cancer, with rates increasing by 22% in individuals with elevated levels. The study recommends limiting cadmium intake through diet and lifestyle changes to reduce associated cancer risks.
Inlighta Biosciences is developing a novel, protein-based MRI contrast agent called ProCA32 to detect early stages of liver cancers and other metastatic tumors. The agent has shown improved imaging contrast compared to conventional agents, enabling earlier detection and characterization of cancerous lesions.
Researchers identified a key signaling pathway causing bile duct cancer and found possibilities to interrupt it. High ROS levels and TNF production promote tumor growth, but antioxidants and JNK inhibitors can stop tumorigenesis.
Exposure to particulate air pollution after liver cancer diagnosis significantly increases risk of premature death. Higher exposure levels further elevate the risk of dying from liver cancer or any cause.
In liver cancer, Scrib's increased expression suppresses the growth of cancer cells by inhibiting three oncogenes. The study provides the first hard evidence that Scrib functions as a tumor suppressor in human and animal liver cancer.
The CheckMate 040 study found that nivolumab produces durable responses with long-term survival rates of up to 59.9% in sorafenib-experienced patients with advanced HCC, regardless of Hepatitis B or C infection status.
Sub-Saharan African-born blacks experience a higher incidence of infection-related cancers and blood cancers compared to US-born non-Hispanic blacks. In contrast, prostate cancer is more prevalent among Western African-born black men, while Eastern African-born blacks have higher rates of liver and thyroid cancer.
Research identifies PPARγ as a critical regulator of metabolism-associated genes in the liver. Inhibition of PPARγ suppresses tumor growth and reduces tumorigenesis in mouse models.
Researchers developed a novel therapy using iPS-cell derived immune cells that produce interferon-β to combat liver cancer. The treatment was found to inhibit tumor cell proliferation and cause death, with high concentrations of IFN-β detected at targeted sites.
Researchers at MIT have developed a way to detect aflatoxin exposure by sequencing DNA of liver cells, potentially leading to earlier diagnosis and treatment. The technique can identify rare mutations caused by aflatoxin long before tumors form.
Sanford Simon at Rockefeller University has received a $600,000 grant from the Fibrolamellar Cancer Foundation to develop a therapy for fibrolamellar hepatocellular carcinoma. The disease typically affects adolescents and young adults with no history of liver disease, and there is currently no standard treatment regimen.
A new study published in Diabetologia found that having type 2 diabetes increases the risk of death from any form of cancer by 26%, even when controlling for other factors. The research also revealed statistically significant links between T2D and specific cancers, including liver, pancreas, breast, kidney, and endometrium.
A recent study discovered that liver cancer drugs fail because the body lacks a balance between two enzymes, Shp2 and Pten. This imbalance activates molecules involved in lipid metabolism, inflammation, and fibrosis, leading to liver disease and cancer.
A new study found that cancer cases are growing at an alarming rate in less developed countries, with a 50% increase between 2005 and 2015. The global burden of disease is heaviest for countries with high development levels, but the most rapid escalation can be seen in low-income nations where health services are often lacking.
Researchers have developed a new minimally invasive approach using gold nanoparticles encapsulated by gum Arabic to target and destroy precancerous tumor cells in the livers of mice. The study shows that this 'green' nanotechnology approach can suppress liver preneoplastic lesions with minimal damage to healthy tissue.
Researchers found that jet lag increases both obesity-related liver disease and liver cancer risk by disrupting the body's internal homeostasis. The study suggests that lifestyle changes leading to chronic jet lag can also increase liver cancer risk in humans.
A new study from UT Southwestern Medical Center found that proactive outreach to cirrhosis patients doubled their screening rates for liver cancer. The study successfully improved early detection and survival rates among those at highest risk of adverse outcomes. Only one-fourth of cirrhosis patients are currently screened every six mo...
New report predicts 7,100 cancer deaths annually by 2035 linked to alcohol, with oesophageal cancer seeing largest increase. The NHS will face a £2 billion treatment bill, while over 1.2 million hospital admissions are forecasted.
A study by the University of Leeds found that Reovirus, a common childhood cough virus, can stimulate the body's immune system to kill off liver cancer cells and the hepatitis C virus. The researchers hope to start clinical trials to test its effectiveness in treating primary liver cancer.
A large prospective cohort study found associations between high BMI, waist circumference, and type 2 diabetes with increased risk for liver cancer. The study, published in Cancer Research, adds substantial support to the link between obesity-related cancers, including liver cancer.
A new study by Thomas Jefferson University shows that community outreach workers may help increase hepatitis B vaccine uptake among Asian Americans, reducing the risk of liver cancer. The program involved lay health workers who provided personalized calls to encourage vaccinations.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that a key signaling protein helps suppress inflammation and scarring in the liver. The study suggests that p62, which is usually absent from cells that initiate inflammatory signals, plays a crucial role in preventing liver cancer progression.
Researchers at the University of Edinburgh have identified Notch 3 as a key driver of bile duct cancer. The molecule triggers a pathway that drives cells in tumours to reproduce uncontrollably, offering potential for new treatments.
Researchers from Charité have found that high blood selenium levels are associated with a decreased risk of developing liver cancer. Selenium deficiency is identified as a major risk factor for liver cancer, with the third of the population having lowest selenium status facing a five- to ten-fold increased risk.
Researchers developed an algorithm called JAMMIT that uses advanced mathematics to identify patterns across multiple molecular data types. The algorithm can accurately predict which patients would benefit most from chemotherapy and combining it with immunotherapy, leading to improved clinical outcomes and reduced costs.
Researchers found that low doses of paclitaxel, a widely used breast cancer treatment, can actually increase cancer spread to the liver. This contradicts previous strategies of lowering dosage to reduce toxic side effects.
Researchers block glutamine breakdown in liver cancer cells, preserving normal cells, and reduce tumor development in mice. The study identifies LRH-1 as the key protein involved and suggests it as a new target for treating liver cancer.
Researchers from Thomas Jefferson University have identified a panel of microRNAs in blood samples that can predict patients at high risk of developing hepatocellular carcinoma, the most common type of liver cancer, in individuals infected with hepatitis B virus.